Water Soluble Ball Delivers Accurate Quantitative Microbiological Control
By LabMedica International staff writers Posted on 04 Jan 2011 |
Image: The bioMérieux BioBall (photo courtesy bioMérieux).
A small, water-soluble ball containing a precise number of microorganisms, delivers unprecedented accuracy for quantitative microbiological quality control.
Dubbed BioBall, the standard ball products are derived from strains sourced from internationally recognized culture collections.
bioMérieux, (Marcy l'Etoile, France), a leader in the field of in vitro diagnostics (IVD) and in microbiological control for the biopharma and food industries, developed BioBall to provide pharmaceutic microbiology laboratories with their own isolates in a convenient, easy-to-use format.
Many pharmaceutic companies implement standard operating procedures that incorporate several representative strains from among their own bacterial and fungal isolates (from environmental monitoring, sterility, or bioburden testing). Maintaining these strains in-house is time-consuming and costly compared with the quality control (QC) strains such as BioBall that are available for routine use.
BTF (Sydney, Australia), a bioMérieux company, developed the BioBall Plant Isolate service in response to changing practices in culture media quality control for validation and routine testing. BioBall Plant Isolate will enable customers to implement best practices in media QC for their critical environmental monitoring and sterility testing.
BioBall mixed kits contain the most relevant pharmacopeia strains required for quantitative microbiology. Three different products for pharmaceutic QC are available: BioBall SingleShot, BioBall MultiShot 550, and BioBall MultiShot 10E8
BioBall SingleShot mixed kit and BioBall MultiShot 550 mixed kit contain two vials of Aspergillus brasiliensis, two vials of Bacillus subtilis, one vial of Candida albicans, one vial of Escherichia coli, two vials of Pseudomonas aeruginosa, and two vials of Staphylococcus aureus.
BioBall MultiShot 10E8 contains the same mixture of bacteria without C. albicans.
Related Links:
bioMérieux
BTF
Dubbed BioBall, the standard ball products are derived from strains sourced from internationally recognized culture collections.
bioMérieux, (Marcy l'Etoile, France), a leader in the field of in vitro diagnostics (IVD) and in microbiological control for the biopharma and food industries, developed BioBall to provide pharmaceutic microbiology laboratories with their own isolates in a convenient, easy-to-use format.
Many pharmaceutic companies implement standard operating procedures that incorporate several representative strains from among their own bacterial and fungal isolates (from environmental monitoring, sterility, or bioburden testing). Maintaining these strains in-house is time-consuming and costly compared with the quality control (QC) strains such as BioBall that are available for routine use.
BTF (Sydney, Australia), a bioMérieux company, developed the BioBall Plant Isolate service in response to changing practices in culture media quality control for validation and routine testing. BioBall Plant Isolate will enable customers to implement best practices in media QC for their critical environmental monitoring and sterility testing.
BioBall mixed kits contain the most relevant pharmacopeia strains required for quantitative microbiology. Three different products for pharmaceutic QC are available: BioBall SingleShot, BioBall MultiShot 550, and BioBall MultiShot 10E8
BioBall SingleShot mixed kit and BioBall MultiShot 550 mixed kit contain two vials of Aspergillus brasiliensis, two vials of Bacillus subtilis, one vial of Candida albicans, one vial of Escherichia coli, two vials of Pseudomonas aeruginosa, and two vials of Staphylococcus aureus.
BioBall MultiShot 10E8 contains the same mixture of bacteria without C. albicans.
Related Links:
bioMérieux
BTF
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia